CoChat

The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.

The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer

Open access

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10555-024-10192-9

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The link between cancer, obesity, diabetes, and GLP-1R’s effect on them. Generated using BioRender
Fig. 1 The link between cancer, obesity, diabetes, and GLP-1R’s effect on them. Generated using BioRenderCC BY · PubMed Central
Fig. 2 Effects of GLP-1RAs on organs. GLP-1R and agonists decrease hypertension, atherosclerosis, inflammation, plasma glucose levels, prostate cancer progression, insulin levels, albuminuria, renal failure progression, steatosis, gastric and acid secretion, and gastric motility levels amongst various organs in the body. GLP-1R and agonists increase heart rate regulation, vasodilation, oxidative stress regulation, pulmonary surfactants, β cell proliferation, insulin secretion and sensitivity, medullary thyroid cancer, diuresis, natriuresis, fat metabolism, neuronal excitability, energy expenditure, stress response, satiety, and visceral illness. For breasts, GLP-1R and agonists lead to an increase or decrease in breast cancer progression. Generated using BioRender
Fig. 2 Effects of GLP-1RAs on organs. GLP-1R and agonists decrease hypertension, atherosclerosis, inflammation, plasma glucose levels, prostate cancer progression, insulin levels, albuminuria, renal failure progression, steatosis, gastric and acid secretion, and gastric motility levels amongst various organs in the body. GLP-1R and agonists increase heart rate regulation, vasodilation, oxidative stress regulation, pulmonary surfactants, β cell proliferation, insulin secretion and sensitivity, medullary thyroid cancer, diuresis, natriuresis, fat metabolism, neuronal excitability, energy expenditure, stress response, satiety, and visceral illness. For breasts, GLP-1R and agonists lead to an increase or decrease in breast cancer progression. Generated using BioRenderCC BY · PubMed Central
Fig. 3 Liraglutide and Exendin-4 decrease NF-κB, cell proliferation, and phosphorylated ERK in cancer. Liraglutide decreases Pl3K, Akt/PKB, and cell division while increasing GLP-1Rs, NOX4, ROS, caspase, MAPK, cAMP, Bcl-2, PKA, and cell apoptosis levels. Exendin-4 decreases Cylin D1 while increasing GLP-1Rs, MAPK, p21, p53, cAMP, Bcl-2, and cell apoptosis. Generated using BioRender
Fig. 3 Liraglutide and Exendin-4 decrease NF-κB, cell proliferation, and phosphorylated ERK in cancer. Liraglutide decreases Pl3K, Akt/PKB, and cell division while increasing GLP-1Rs, NOX4, ROS, caspase, MAPK, cAMP, Bcl-2, PKA, and cell apoptosis levels. Exendin-4 decreases Cylin D1 while increasing GLP-1Rs, MAPK, p21, p53, cAMP, Bcl-2, and cell apoptosis. Generated using BioRenderCC BY · PubMed Central
Fig. 4 GLP-1R agonists were studied in thyroid cancers. Both Liraglutide and Exendin-4 increase the levels of GLP-1R, RET/PTC, mTOR, and calcitonin expression amongst patients with thyroid cancer. Generated using BioRender
Fig. 4 GLP-1R agonists were studied in thyroid cancers. Both Liraglutide and Exendin-4 increase the levels of GLP-1R, RET/PTC, mTOR, and calcitonin expression amongst patients with thyroid cancer. Generated using BioRenderCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 125 references

Research works printed but not linked: 5

  1. Johnson, L. R., Barret, K. E., Gishan, F. K., Merchant, J. L., Said, H. M., & Wood, J. D. (2006). Physiology of the gastrointestinal tract; ; Vol. 1–2.
  2. Koehler, J. A., Kain, T., & Drucker, D. J. (2011). Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology, 152,. https://doi.org/10.1210/en.2011-1201 · DOI
  3. Iwaya, C., Nomiyama, T., Komatsu, S., Kawanami, T., Tsutsumi, Y., Hamaguchi, Y., Horikawa, T., Yoshinaga, Y., Yamashita, S., Tanaka, T., et al. (2017). Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-ΚB activation. Endocrinology, 158, 4218–4232. https://doi.org/10.1210/EN.2017-00461 · DOI
  4. Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2022). Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetology International, 13, 480–492. https://doi.org/10.1007/s13340-021-00560-z · DOI
  5. Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015). Combined treatment with exendin-4 and metformin attenuates prostate cancer growth. PLoS One, 10, e0139709. https://doi.org/10.1371/journal.pone.0139709 · DOI

Cited by

See all 73

Metadata

Authors
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D.
Affiliations
  • Weill Cornell Medical College in Qatar (QA)
  • Anatomische Anstalt (DE)
Corresponding author
Büsselberg, Dietrich
Venue
Cancer and Metastasis Reviews
Published
2024-05-27
Volume
43
Issue
4
Pages
1297-1314
ISSN
  • 0167-7659 (ISSN-L)
  • 1573-7233
OpenAlex
W4399046314
Cited by
56
References
125
Citations by year
2026: 26 · 2025: 27 · 2024: 3
FWCI
3.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer and Metastasis Reviews (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
Funders
  • Qatar National Research Fund (NPRP 14S-0311–210033)
  • Weill Cornell Medical College in Qatar
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, obesity, type 2 diabetes, cancer, semaglutide, glucose homeostasis, beta-cell proliferation, insulin secretion, appetite regulation, cancer risk, signaling pathways
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. https://app.cochat.ai/papers/10.1007/s10555-024-10192-9
The paper
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024). The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-024-10192-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.